APG-115 Clinical Trials

4 actively recruiting trials across 1 location

Pipeline

Phase 1: 2Phase 2: 1Phase 1/2: 1

Top Sponsors

Ascentage Pharma Group Inc.4

Indications

Cancer4
Non-Hodgkins Lymphoma1
T-Prolymphocytic Leukemia1
Myelodysplastic Syndromes (MDS)1
Liposarcoma1

Other3 trials

A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.

Phase 1

APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors

Phase 1

APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors

Phase 1/2

Houston, Texas1 trial

A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL

MD Anderson

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.